Novartis CEO Vas Narasimhan is giving the Swiss pharma a huge makeover even ahead of a possible spinoff of generics unit Sandoz, pushing out three …
Gilead Sciences has a lot of its oncology ambitions riding on Trodelvy’s success beyond its existing approvals. While investors have been waiting with bated breath …
With the acquisition of the U.S. sales and distribution rights of eight cardiovascular drugs from Daiichi Sankyo, Cosette Pharma of New Jersey is making a …
Amid its push to grow around the globe in oncology, rare diseases and neuroscience, Ipsen has poached a Novartis veteran to head up its international …
Current and future cancer treatment is expected to be shaped and guided by the use of biomarkers that will guide researchers and physicians at every …
New Network Builds on Success of the Company’s Early Phase, Oncology, Psychiatry and Vaccine Catalyst Site Networks Syneos Health™ (Nasdaq: SYNH), the only fully integrated …
NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate …
NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of …
Tianhe Life Sciences leads $9.5m Series A in Clover Biopharma Clover is utilising its proprietary Trimer-Tag technology platform to develop biologics targeting trimerization-dependent pathways. Clover …
Nanobiotix, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data from the ongoing immuno-oncology programs. …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
